论文部分内容阅读
目的比较紫衫类药物联合葱环类与单用葱环类方案辅助化疗对乳腺癌术后患者的疗效分析。方法选取我院自2006年4月至2007年12月乳腺癌术后患者120例,随机分为治疗组60例,对照组60例,分析其临床持征、病理学持征及化疗方案与复发转移率的关系,并进一步分析紫衫类药物化疗对ERPR阴性患者的疗效。结果所有病例均随访至2011年5月,无1例随访丢失,总复发转移率为28.3%,死亡率为15%。其中蒽环类加紫杉类辅助化疗者与单纯蒽环类辅助化疗者的复发转移率分别为20%、36.7%,两组差异有显著性意义,P<0.05;两组的死亡率分别为11.7%(7/60)和18.3%(11/60),差异有统计学意义,P<0.05。ER、PR受体阴性的患者,蒽环类加紫杉类方案化疗者复发转移率明显低于单用蒽环类方案复发转移率,二者相比差异有统计学意义;而对ER或/和PR阳性者,两种化疗方案差异无统计学意义。结论在常规葱环类化疗方案中加入紫衫类药物可以降低乳腺癌术后患者的复发风险,持别对ER、PR均阴性的患者有明显无病生存优势。
Objective To compare the curative effect of the combination therapy of the combination of the purple collard medicine with the onion ring and the single onion ring program on postoperative patients with breast cancer. Methods A total of 120 patients with postoperative breast cancer from April 2006 to December 2007 in our hospital were randomly divided into treatment group (60 cases) and control group (60 cases). The clinical manifestations, pathological symptoms, chemotherapy regimens and relapse Metastatic rate, and further analysis of the efficacy of the treatment of ERPR-negative patients. Results All patients were followed up until May 2011, none of them were lost at follow-up. The total recurrence and metastasis rate was 28.3% and the mortality rate was 15%. The recurrence and metastasis rates of anthracycline plus taxane adjuvant chemotherapy and anthracycline chemotherapy alone were 20% and 36.7%, respectively, with significant difference between the two groups (P <0.05). The mortality rates of the two groups were 11.7% (7/60) and 18.3% (11/60) respectively, the difference was statistically significant, P <0.05. In patients with ER and PR receptor negative, the recurrence and metastasis rate of anthracycline plus taxane regimen was significantly lower than that of anthracycline alone regimen, the difference was statistically significant; while ER and / And PR-positive, the two chemotherapy was no statistically significant difference. Conclusion Adding the drug to the conventional alliin regimen can reduce the risk of recurrence in postoperative patients with breast cancer, and there is a clear advantage of disease-free survival in patients with negative ER and PR.